Clinical trials: Hepatic Tumors
Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
HCC is an aggressive, largely chemo-resistant cancer with a poor prognosis, currently there is no effective systemic chemotherapy for HCC.
- Trial name
- SECOX (NCT00752063)
- Testing
- Sorafenib with Capecitabine and Oxaliplatin
- Where
- China
- Volunteers
- 52 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma (HCC)
Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis
Abbreviated MRI (AMRI) could improve the diagnostic performance of hepatocellular carcinoma (HCC), but it lacks analysis in different subgroups and effective validation.
- Trial name
- AMRI; LIRADS (NCT06663904)
- Where
- China
- Volunteers
- 938 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Portal Vein Thrombosis
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
This study is investigator initiated, single-institution, prospective, phase 2 open-label study to determine the efficacy and safety of combination therapy of atezolizumab/bevacizumab and proton beam therapy to portal vein tumor…
- Trial name
- NCT05625893
- Testing
- PBT and atezolizumab/bevacizumab
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma, Hepatoma
Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver
The diagnostic accuracy of EUS for detection of the liver tumors (primary and metastatic) remains unknown. To compare the accuracy of the EUS and CT scan for detection of the primary and metastatic carcinoma of the liver.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Cholangiocarcinoma, Liver Metastases
- Trial name
- NCT00290316
- Testing
- Endoscopy ultrasound
- Where
- United States
- Sponsor
- Central Texas Veterans Health Care System
Liver Carcinoma, Hepatocellular Carcinoma
Combined HCC-MFCCC
Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming…
- Conditions
- Liver Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Surgery
- Trial name
- NCT03178409
- Testing
- Hepatectomy
- Volunteers
- 100 people
- Sponsor
- University of Milan
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
Cancer of Liver, Cancer of Colon
Getting To Implementation: Improving Cancer Screening for Veterans
Gastrointestinal cancers such as colon cancer and liver cancer cause many deaths in the US. Testing could catch these cancers early, helping people live longer.
- Conditions
- Cancer of Liver, Cancer of Colon, Cirrhosis
- Trial name
- GTI (NCT06458998)
- Testing
- Patient Navigation, Implementation Facilitation
- Where
- United States
- Volunteers
- 30,300 people
- Sponsor
- University of Pittsburgh
Neoplasm, Liver
Open Versus Laparoscopic Left-sided Hepatectomy Trial
Open versus Laparoscopic Left-sided Hepatectomy (OLLEH) trial Multi-institutional, prospective and randomized trial in patients undergoing left sided hepatectomy through laparoscopic versus open procedure.
- Trial name
- OLLEH (NCT03010085)
- Testing
- Open left-sided hepatectomy, Laparoscopic left-sided hepatectomy
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Liver Cancer
Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)
To evaluate the additional efficacy and safety of oral enterobacterial capsules in patients with intermediate and advanced liver cancer and treated with tyrosine kinase inhibitors (TKIs) combined with immunotherapy.
- Trial name
- NCT06563934
- Testing
- Oral enterobacterium capsules, Lenvatinib + PD-1 monoclonal antibody
- Volunteers
- 70 people
- Sponsor
- Xu Yong, MD
Hepatocellular Carcinoma, Radiation Exposure
Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment
The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC)…
- Trial name
- NCT03686709
- Testing
- Post therapy PET/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Tennessee
Carcinoma, Hepatocellular, Neuroendocrine Tumors
Circulating Tumor Cells and Tumor DNA in HCC and NET
Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies.
- Trial name
- NCT02973204
- Testing
- Sorafenib, Radiofrequency ablation (RFA) or surgery, Everolimus
- Where
- Denmark
- Volunteers
- 167 people
- Sponsor
- University of Aarhus
Carcinoma, Hepatocellular
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC.
- Trial name
- NCT02323906
- Testing
- CC-122, Sorafenib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Hepatocellular Carcinoma, Liver Cancer
TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma
The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined.
- Conditions
- Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Primary Liver Cancer
- Trial name
- TheraSphere (NCT00906984)
- Testing
- TheraSphere
- Where
- United States
- Sponsor
- University of California, Irvine
Hepatocellular Carcinoma
AFP- L3% and DCP as Tumor Markers in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolisation (TACE)
Hepatocellular carcinoma (HCC) is one of the tumors with an increasing incidence worldwide. Often treatment possibilities are limited and only palliative treatment such as a transarterial chemoembolisation (TACE) is possible.
- Trial name
- NCT01360255
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Freiburg
Carcinoma, Hepatocellular
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
- Trial name
- HCC (NCT01141478)
- Testing
- Proton Beam Radiotherapy, Sorafenib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Hepatocellular Carcinoma (HCC)
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
A Study of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients with Unresectable Recurrent/Metastatic Hepatocellular Carcinoma.
- Trial name
- NCT07487402
- Testing
- Metabolically Armed GPC3 CAR-T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Zhejiang University
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Laser Ablation
Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Conditions
- Hepatocellular Carcinoma, Laser Ablation, Portal Vein Tumor Thrombus
- Trial name
- NCT02724475
- Testing
- LA, 3D-CRT
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Surgery, Liver Metastases
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
The aim of the study is to investigate if iv iron formulation improve recovery after surgery with blood loss. Post-operative anaemia is a common debilitating condition after major surgery due to a combination of preoperative iron…
- Conditions
- Surgery, Liver Metastases, Liver Cancer, Pancreas Cancer
- Trial name
- IRIS (NCT05744219)
- Testing
- Ferric carboxymaltose
- Where
- Sweden
- Volunteers
- 338 people
- Sponsor
- Jon Unosson
Hepatocellular Cancer, Pancreatic Cancer
High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of high-dose vitamin C combined with metformin in the treatment of malignant tumors.
- Conditions
- Hepatocellular Cancer, Pancreatic Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04033107
- Testing
- Vitamin C, Metformin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongnan Hospital